Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.39 |
| ▸ | ITGAV | P06756 | 11/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | ITGB6 | P18564 | 5/20 | 0.37 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | NNMT | P40261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12158643 | 0.83 | ITGB3 (0.36) | ITGB3ITGAVITGB6ITGB5ITGB1 | |
| SCHEMBL16607409 | 0.83 | ITGB3 (0.36) | ITGB3ITGAVITGB6ITGB5ITGB1 | |
| SCHEMBL20091210 | 0.80 | UHRF1 (0.36) | ITGB3ITGAVITGB6ITGB5CXCR4 | |
| SCHEMBL10258928 | 0.79 | NPC1 (0.39) | ITGB3ITGAVITGB6CXCR4ITGA2B | |
| SCHEMBL325441 | 0.79 | NPC1 (0.39) | ITGB3ITGAVITGB6CXCR4ITGA2B | |
| SCHEMBL325440 | 0.79 | NPC1 (0.39) | ITGB3ITGAVITGB6CXCR4ITGA2B | |
| SCHEMBL18105218 | 0.76 | ITGB3 (0.33) | ITGB3ITGAVITGB6ITGB5CXCR4 | |
| SCHEMBL21329809 | 0.76 | ITGAV (0.36) | ITGB3ITGAVITGB6ITGB5CXCR4 | |
| SCHEMBL24194417 | 0.75 | ITGAV (0.35) | ITGB3ITGAVITGB6ITGB5ITGB1 | |
| SCHEMBL25989073 | 0.75 | ITGAV (0.35) | ITGB3ITGAVITGB6ITGB5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250009915-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORPORATION (JP) | 2025-01-09 | — | — | US | disclosed |
| CN-117903171-A | Integrin inhibitors of a class of bicyclic derivatives | 上海如凌生物医药有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4249471-A2 | PHARMACEUTICAL COMPOSITION OF A NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM Corporation (JP) | 2023-09-27 | — | — | EP | disclosed |
| EP-3929196-B1 | PHARMACEUTICAL COMPOSITION OF A NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORP (JP) | 2023-08-23 | — | — | EP | disclosed |
| EP-3929196-B1 | PHARMACEUTICAL COMPOSITION OF A NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORP (JP) | 2023-08-23 | — | — | EP | disclosed |
| US-20230136073-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORPORATION (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20230136073-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | FUJIFILM CORPORATION (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11426473-B2 | Nitrogen-containing compound or salt thereof, or metal complex thereof | FUJIFILM CORPORATION (JP) | 2022-08-30 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-6297249-B1 | SUBSTITUTED 2-CARBOXYALKYLPYRIDINES | MERCK & CO., INC. | 2001-10-02 | — | — | US | disclosed |
| WO-2001024797-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2001-04-12 | — | — | WO | disclosed |
| EP-0934305-A4 | INTEGRIN ANTAGONISTS | MERCK & CO INC (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6211184-B1 | TETRAHYDRO-PYRAZINE OR PYRIMIDINE DERIVATIVES; VITRONECTIN RECEPTOR ANTAGONIST; OSTEOPOROSIS; ANTIINFLAMMATORY, ANTITUMOR AGENTS; ANGIOGENESIS AND RESTENOSIS INHIBITORS | MERCK & CO., INC. | 2001-04-03 | — | — | US | disclosed |
| WO-2001000578-A1 | 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000072801-A2 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-12-07 | — | — | WO | disclosed |
| US-6048861-A | OSTEOPOROSIS; BONE DISORDERS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATROY AGENTS; WOUND HEALING AGENTS | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | disclosed |
| US-5981546-A | Integrin antagonists | MERCK & CO., INC. (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0934305-A1 | INTEGRIN ANTAGONISTS | Merck & Co., Inc. (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998008840-A1 | INTEGRIN ANTAGONISTS | MERCK & CO., INC. (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136073-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | SLC39A3, SLC39A14, SLC39A11 | ITGB3 2323/4885ITGAV 3525/4885CCR1 366/4885 |
| US-11426473-B2 | Nitrogen-containing compound or salt thereof, or metal complex thereof | SLC39A3, SLC39A14, SLC39A11 | ITGB3 2015/4885ITGAV 3495/4885CCR1 285/4885 |
| US-20250009915-A1 | NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF | SLC39A3, SLC39A14, SLC39A11 | ITGB3 2366/4885ITGAV 3539/4885CCR1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.